Dr. Wood row Responds

摘要

Following publication of Lee et al.'s observational study showing a superior patient survival~(TM) patients receiving the Low glucose degradation product solution, Balance (Fresenius Medical Care, St. Wendel, Germany) (1), it is encouraging to hear that a sizeable, randomized controlled trial of this solution (the balANZ Trial) has been initiated, looking at a primary end point of change in residual renal function (RRF). Brown and Johnson point out that, to determine a survival advantage for a biocompatible solution with adequate power, a larger study (they estimate over 600 patients) would be required. However, a study providing robust data on the effect of new biocompatible solutions on other clinically important end points would be of great clinicalsig-nificance. If positive, evidence that biocompatible solutions can provide tangible benefits in patient outcomes could help to justify their more routine usein clinical practice.